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patients	that	would	qualify	for	such	treatment	need	to	be	identified. Hence the need for a 
DMD specific disease registry 
Objective: This study aim to describe the concept and design of the first DMD disease 
registry of South Africa using Research Electronic Data Capture (REDCap)   
Methods: A comprehensive literature review was undertaken to identify the key areas 
of DMD, which must be recorded to permit comparison across disease expression and 
intervention variables. The registry was developed using REDCap’s web based online 
designer accessed through the Clinical Research Centre (CRC) in the Faculty of Health 
Sciences at the University of Cape Town, and the workflow methodology was adopted 
to manage the registry. Clinical data from DMD patients form the database and consists 
of seven parts: 1) Enrolment details, 2) Background data, 3) Current disease, 4) 
Schooling, career prospects, and life style/psychological details, 5) basic activity of 
living scale, 6) power chart,7) current motor function/symptoms. Electronic case report 
forms were created from these clinical data by the use of REDCap and for specific 
variables serial entries were possible relating to disease progression. We adopted 
international data standards proposed by TREAT-NMD, a global network of registries 
on DMD to ensure our data is internationalised and comparable to other registries. 
Results: Retrospective data entry combined with dynamic prospective recording of 
data was utilized in this project. Building on an existing basic database, 100 confirmed 
DMD boys are currently eligible for inclusion into the registry. 
The registry database consist of 7 forms collecting information on clinical and genetic 
information, which is subdivided into 100 items making a total of 210 variables. As our 
registry is an on-going study, sequential analysis of accumulated data will done going 
forward to review trends on our DMD patients. 
 
Conclusions: This work describes the concept and design of our DMD registry and the 
steps followed to its establishment with REDCap. The focus is to consolidate clinical 
and genetic information on South African DMD patients that will translate to clinical 
research and form the basis for this patient information to be linked nationally and 
internationally. It is the hope that such an effort can be replicated in the 
conceptualisation of new disease registries 
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8) Chapter 1: INTRODUCTION AND LITERATURE REVIEW 
8.1 Introduction 
The most frequent form of muscle dystrophy found in childhood is Duchenne Muscular 
Dystrophy (DMD) and it is the most severe in the spectrum of muscle diseases termed 
the dystrophinopathies. The natural (untreated) history of DMD comprises: delayed 
milestones (sitting, standing), mean age of walking 18 months, mean age of diagnosis 5 
years, proximal skeletal muscle weakness and waddling gait with difficulty climbing 
stairs, and wheelchair bound by 12 years. A milder form in the spectrum of 
dystrophinopathies is Becker muscular dystrophy (BMD), with delayed skeletal muscle 
weakness of later-onset, and preserved neck flexor muscle strength (unlike DMD), and 
patients remaining ambulatory until beyond 20 years of age. Wheelchair dependency 
occurs in DMD before 13 years, whereas it occurs in BMD after 16 years; this 
differentiates the two. There is a third clinically important dystrophinopathy, where 
cardiac muscle is predominantly affected and it is called DMD-associated dilated 
cardiomyopathy (DCM). This is a distinct entity where, reportedly, males present 
between 20 and 40 with cardiac failure, although we have seen at least one patient 
presenting in our service with heart failure at the age of 14 years; DCM can also be 
seen in at risk female carriers of DMD mutations. 
The primary problem is a mutation in the dystrophin gene located on chromosome X 
(Xp21.2) and the inheritance is via X-linked recessive fashion. 
 Gene therapy is a technique, which involves treating a genetic disease by altering the 
defective gene.  The possibility of gene therapy and experimental genetically driven 
interventions in DMD has been investigated for some time and great progress has been 
made.  A crucial aspect of the treatment is that the genetic defect needs to be 
characterized.  
 Since January 2007, TREAT-NMD, through collaboration has enabled experts to come 
together and to establish common standards of care, bringing together the 
neuromuscular community to speed up clinical trials and increase awareness of rare 
diseases such as Duchenne Muscular Dystrophy. 
The dedicated neuromuscular service at Red Cross War Memorial Children’s Hospital 
manages the single largest collection of boys with DMD in sub-Saharan Africa. The 
service operates in line with international recommendations as a multidisciplinary 
service with input from ancillary services, pulmonology, cardiology, developmental, 
orthopaedics, endocrinology, histopathology, genetics and counsellors.  With the 
possibility of treatment becoming available, patients that would qualify for treatment 
need to be identified.  The service has established a database of these children with 
confirmed DMD, but there is a need to consolidate the information in the database to 
form a patient registry. 
DMD is a rare disease, and therefore, it will take many years to find eligible patients for 
trial without a registry. The South African DMD (SADMD) registry is the first local 
attempt to consolidate clinical and genetic information on South African DMD patients 
with the potential to be considered for contemporary clinical trials and be well 
informed regarding the most up to date standards of care. This cohort will provide the 
biggest longitudinal data collection of DMD boys in Africa with the possibility of links 






8.2 Objectives  
The cardinal objectives of the SADMD registry are, to update and expand the existing 
database.  
• To populate it with current information relating to the clinical phenotypes of the 
patients inclusive of their cardiac, respiratory, cognitive, oromotor / 
gastroenterological, motor and orthopaedic evolution.  
• To assess the effect of introduction of corticosteroids and cardiac interventions 
on the course of these children for their cardiac and pulmonary, duration of 
ambulation, orthopaedic complications and resultant need for BIPAP support.  
• To correlate the clinical profile of this patient group with those who have 
confirmed genetic mutations and identify those who may be remedial for the 
latest gene therapy and who would benefit from extended screening to confirm 
if this is the case.  
• To establish if the South African cohort carry a similar range of mutations 
compared to those listed internationally 
• To see if direct relationship can be identified between specific mutation and 
clinical course  
• To identify if the range of patients carrying potentially remedial gene therapy 
mutations is in-line with the incidence reported internationally 
 
8.3 Search Strategy 
The literature review, which was done in May 2015 and repeated in February 2017, 
Was done using mostly Ebscohost, Pubmed, and Web of Science. The search terms 
included key words: [Rare disease] [Rare disease registry] [Disease registries] 
[Duchenne muscular Dystrophy] [Treat NMD][REDCap]. Bibliographic references of 
important articles were also manually searched for added publications. 
Articles were included if they studied rare disease registries, registry design and 
concepts, and all in the English language. 
 
8.4 Search Results 
In total, 50 articles resulted from the search above, of which 42 full articles were were 
reviewed and 35 included in the literature review. At the same time, a further 48 
articles were found   and added from the Bibliographic reference list. 
8.5 Background Information 
Dystrophinopathy is the umbrella term for a group of inherited progressive muscle 
disorders due to mutation in the dystrophin gene on the X-chromosome (Xp21.2) and 
required for a normal muscle function (1) (2, 3). Mutation in this gene results in no or 
abnormal dystrophin in muscles and this manifest as muscle weakness (1, 3). 
The identification of the dystrophin gene in the 1980’s, led to the characterization of a 
number of muscular dystrophy genes and their protein products. The information on the 
molecular basis of muscular dystrophies resulted in better understanding of the disease 
mechanisms and improved diagnosis, both in the clinic and in the laboratory. This 
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knowledge has led to the availability of more reliable and informative genetic testing, 
which allows for more effective patient management and accurate genetic counseling of 
families (4). 
The allelic Duchenne and Becker muscular dystrophies (D/BMD) remain lethal and 
devastating to patients and their families, despite recent advances in medical 
technology (3). While standards of care are continually improving worldwide, currently 
available interventions are limited to the management of symptoms and complications. 
Progress in terms of therapy has been slow and fraught with pitfalls and setbacks. 
However, much research has been focused on genetic therapies, and in recent years a 
number of new experimental approaches appear to hold promise. Of those, read-
through therapy and exon skipping are especially relevant to D/BMD (3, 5, 6). 
Nonetheless, the first step remains identification of the disease-causing mutations. 
Potential availability of mutation-specific gene therapy marks the advent of 
personalised medicine and emphasizes the need for a rapid and accurate method of 
detecting small nucleic acid changes in D/BMD and other genetic disorders.  
MUSCULAR DYSTROPHIES 
Neuromuscular diseases are a well-defined spectrum of heterogeneous, hereditary 
disorders, characterised by on-going weakness and wasting of skeletal muscle tissues 
(3, 7). Muscular dystrophies form part of this spectrum. The main groups in the 
spectrum are: 
• Duchenne/Becker-type (X-linked)
• Facioscapulohumeral (autosomal dominant)
• Limb girdle (genetically heterogeneous but mostly autosomal recessive)
• Emery-Dreifuss (X-linked, autosomal dominant and recessive sub-types)
• Distal (autosomal dominant and recessive clinically and genetically distinct
subgroups)
• Oculopharyngeal (autosomal dominant)
• Congenital (autosomal recessive with a more generalised muscle weakness)
This Classification scheme devised by Walton and Nattrass in 1954, based on their own 
clinical observations and still applied today, relies mostly on the distribution of muscle 
weakness (Figure1), and the mode of inheritance (3, 7) 
Muscular dystrophies have since been mapped to 29 different chromosomal loci, 
shifting the above classification into 34 different disorders with difference in the age of 
first symptoms, degree of severity, pattern of inheritance and the predominantly 




Figure 1: Different types of Muscle dystrophy with typical distribution of predominant 
muscle weakness:  
  A: Duchenne-type and Becker-type, B: Emery-Dreifuss, C: limb-girdle, D: 
facioscapulohumeral, E: distal, F: oculopharyngeal. Shaded=affected areas (3). (1, 9, 
10) Reproduced with permission from Alan E H Emery, muscular dystrophies, BMJ, Oct 
10.1998, vol 317, Liscense number 4106711480102(see appendix 6) 







GENETICS OF DUCHENNE/BECKER MUSCULAR DYSTROPHY (D/BMD) 
(OMIM#310200) 
Duchenne Muscular Dystrophy is a genetic disorder with an X-linked recessive 
inheritance (10, 11). This disorder results from mutations (often deletions) in the 
dystrophin gene on the X chromosome (Xp21.2) (1, 10, 12). It has a frequency of 1 in 
3600– 6000 male births (1, 2, 13). The DMD gene is the largest known human gene. It 
is around 2000 kilobases in size and codes for dystrophin, a large, rod-like 427-kD 
protein containing 3685 amino acids and located at the inner face of the muscle cell 
membrane (14-16). Dystrophin interacts with a group of ‘dystrophin-associated 
proteins’ (DAPs) (e.g. sarcoglycans, dystroglycans, merosin) that span the muscle 
membrane, linking the cytoskeleton of the muscle and the extracellular matrix (see 
Figure 2.0). Absence of dystrophin disrupts the link, making the membrane of muscles 
susceptible to damage from shearing forces. Hence, muscles deficient in dystrophin are 




Dystrophin is undetectable in the muscle of DMD patients. With access to MLPA, 70% 
of all DMD mutations are identifiable in males with DMD, making genetic testing 
highly sensitive in clinical settings (17, 18). Over 4700 mutations in the DMD gene 
have been identified. Disease-causing alleles varied and can be complete, involving the 
entire deletion of a gene, exon deletion/duplication, insertions, as well as deletions that 
are small and replacement of a single base (2, 10, 19). Around two thirds of DMD 
patients have intragenic out-of-frame deletions with gross rearrangement, duplications 
of more than one exon of the gene are found in about 10% of patients, the rest have 
small rearrangements including insertions of repetitive sequences, intronic deletions, 
and splice site mutations as well as point mutations (2, 10, 20, 21). 
Generally out-of-frame mutations cause lack of dystrophin (and DMD), whereas in-
frame mutations cause abnormal but partially functional dystrophin, resulting in BMD	
(2,	21,	22). The tissue distribution of dystrophin correlates with clinical features. It is 
found in skeletal, cardiac and smooth muscle, and results in skeletal muscle weakness 
and cardiomyopathy. Abnormal expression of myocardial dystrophin is noted in DMD-
associated DCM, mildly reduced amount of dystrophin in skeletal muscle DMD (23, 
24). Dystrophin is found within the central nervous system, resulting in a static 
encephalopathy and cognitive deficits. Various forms of dystrophin are expressed in 
neurons and glia in the brain, especially the cortex, hippocampus, cerebellum and retina	
(25). Confirmed diagnosis of DMD can be made with molecular genetic testing in 
around 70% of patients with no need for muscle biopsy in these patients. New 
mutations are now showing peak incidence and over 60% of all new mutation have no 
significant family history (24, 26). 
 
GENETIC MUTATIONS AND DYSTROPHIN 
Mutations 
Predominantly, one or more exon deletions constitute dystrophin gene mutations, 
which are found largely in patients with DMD and BMD, (2, 9, 27-29). Reported in 
small proportions of affected individuals are a small percentage of partial gene 
duplications (30) (31)  
The genetic lesions in the remaining patients (ie, without detectable deletions or 
duplications) are single nucleotide variants, small deletions or insertions in the coding 
sequence, or splice site variants. In addition, patients with clinical phenotypes 
consistent with DMD or BMD, but not with an apparent X-linked pattern of 
inheritance, may have defects in other genes, including those encoding the dystrophin-
associated glycoproteins as depicted in figure 2(3, 32). 
The molecular basis for the phenotypic differences among the dystrophinopathies is 
related in part to whether the reading frame for dystrophin is preserved. Disruption of 
the reading frame for dystrophin is the lesion in most cases of patients with DMD while 
those with BMD have mutations that maintain the amino acid coding sequence (32) 
Dystrophin — (figure 2) (33-35). Mechanically, it lends support and protection to the 
sarcolemma and the glycoprotein complex, preventing it from degradation. When 
dystrophin is absent, the glycoprotein complex is exposed to proteases and eventually 
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digested. This process initiates the degeneration of muscle fibres, leading to muscle 
weakness. 
Figure 2: Dystrohin associated protein complex, Reproduced with permission from Alan E H 
Emery, muscular dystrophies, BMJ, Oct 10.1998, vol 317, Liscense number 4106711480102(see 
appendix 6) 
The loss of dystrophin in mdx mice leads to myofibril membrane instability (36). 
However, the dystrophin gene disruption in mdx mice resulted in only a mild dystrophy 
(37). Although the reduced disease severity in mdx mice compared with human DMD 
is not completely understood, several possible explanations are postulated as follows: 
I. A homolog of dystrophin called utrophin is present in mice and humans. Its 
expression in muscle can compensate physiologically for the absence of 
dystrophin in mice, but this compensation does not occur in humans. This 
hypothesis underpines the finding that, mice lacking both dystrophin and 
utrophin have severe dystrophy, which phenotypically resembles DMD (37). 
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Further, the selective expression in skeletal muscle of utrophin via the use of a 
transgene completely rescues these double-knockout mice from early death and 
the DMD phenotype (8). 
II. For sialic acid N-glycolylneuraminic acid (Neu5Gc) to be expressed in humans,
cytidine monophosphate-sialic acid hydroxylase gene (CMAH) is required (38).
However, CMAH is documented as absent in humans because of an inactivating
deletion. But, most mammals, including mice, can express Neu5Gc and
incorporate it onto glycolipids and glycoproteins in skeletal and cardiac muscle,
a factor that may ameliorate disease expression in mdx mice (29). In support of
this theory, disease severity is accelerated and more closely resembles human
DMD if mdx mice also carry mutation in the Cmah gene that looks like the one
found in humans (29).
III. Compared with the murine type, human muscle stem cells have shorter
telomeres, which result in progressive loss of muscle stem cell function. The
severity of human DMD may be due in part to the loss of useful muscle stem
cells, making it impossible to repair the momentous muscle injury that occurs as
part of this disease (39). In support of this hypothesis, “double knockout mice
(mdx/mTR) have shortened telomeres in muscle cells and develop a severe
muscular dystrophy” similar to human DMD (3, 40).
In the the glycoprotein complex of the sarcolema, dystrophin has a number of 
associated proteins, one of which is known as neuronal nitric oxide synthase (nNOS) 
(41). This sarcolemmal synthase enzyme is important for nitric oxide formation, and 
mediates vasodilation leading to increased blood flow into muscles, preventing of early 
muscle fatigue with activity (42-44).  Loss dystrophin is equal to a loss of muscle 
nNOS in their manifestation (41, 45), leading to early muscle fatigue with activity (42-
44, 46). 
Calcium disregulation may sometimes have a role in the disease process of DMD (47-
50). Loss of dystrophin, causing muscle cell membrane damage, may permit 
extracellular calcium into muscle fibers. Besides, mediators of inflammation in 
dystrophic muscle tend to induce nitric oxide synthase (iNOS) expression, making it 
bind and destabilizes sarcoplasmic ryanodine receptors to regulate the flow of calcium 
ion (51-53). As a result, calcium leaks from the sarcoplasmic reticulum to reach the 
cytosol. The accumulated cytosolic calcium has the ability to promote muscle 
proteolysis by activating calpains (53, 54). 
Other genetic modifiers — accumulating data suggest that genes other than 
dystrophin affect disease severity and response to treatment (55-57). As an example, a 
variant of the SPP1 gene promoter region (the G allele of the polymorphism 
rs28357094) is associated with reduced muscle strength and above all, ambulation is 
lost at a younger age in patients with DMD, and appears to be a modulator of 
glucocorticoid treatment response (55, 56). Other reports have found that variants of the 
LTBP4 gene influence at what age ambulation is lost in DMD (56, 57). However, these 
findings require further confirmation in larger genetic studies (58). 
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CLINICAL MANIFESTATIONS OF DMD 
Duchenne muscular dystrophy, is first noticed in boys commonly at the ages of 2 and 5 
years, when parents most often notice a delay in “motor milestones and defining 
symptoms such as difficulty in getting up, frequent falling, toe-walking, gait problems, 
and flat-footedness” (59). About 50% of the affected boys cannot walk independently 
at 18 months (59). 
The natural course of the disease is fairly predictable, although severity varies between 
patients, depending on the causative mutation (8). Clinical examination generally 
reveals calf enlargement (pseudohypertrophy), lumbar lordosis, which disappears on 
sitting, and weakness of the neck flexors. Most DMD patients never learn to jump with 
both feet together. Weakness of the hip and knee extensors causes the typical Gower’s 
manoeuvre: in an effort to stand up from lying on his back, the child needs to turn onto 
his front and push himself erect by moving his hands up his thighs. Muscle weakness is 
progressive, starting with proximal weakness of the lower limbs, moving onto the distal 
lower and then upper limbs, ultimately leading to wheelchair dependence (1, 60). Loss 
of independent ambulation, as defined in DMD occurs by the age of 9 to 12 years, in 
intermediate-type muscular dystrophy (IMD) between age 13 and 16 years and in 
BMD, beyond the age of 16 years, though corticosteroid use has made this data less 
fixed (59). Muscle weakness leads to scoliosis in 90% of the cases, with ultimate loss 
of sitting balance, exacerbated by formation of asymmetric contractures of the 
Achilles tendons and hips. In untreated patients, cardiac and respiratory problems are 
the cause of death at the mean age of 19 years (59). BMD has a later onset with a more 
varied presentation and progression, in some cases showing only mild myalgia and 
muscle cramps with no weakness (61). 
Cardiac involvement is seen in all D/BMD patients but generally remains subclinical 
in the early stages. It is likely that the late presentation of cardiac symptoms is due to 
the decrease in physical activity, relative to the progressive general muscle weakness. 
The spread of fibrosis caused by repetitive strain results in left ventricular dysfunction 
and eventual dilated cardiomyopathy, if left untreated (62). Cardiomyopathy is seen as 
the determinant of survival in BMD patients, with an incidence of approximately 72%. 
Research has found that 20% of DMD, and 50% of BMD patients die from 
cardiomyopathy (60, 63). 
For the most part, respiratory function in D/BMD patients is normal before loss of 
ambulation. As a rule, early loss of ambulation predicts early need for ventilation 
support and respiratory failure. The respiratory function parameter in D/BMD patients 
is the Forced Expiratory Volume in one second (FEV1) and forced vital capacity 
(FVC), which peaks shortly before loss of independent ambulation and progressively 
drops thereafter, with eventual respiratory failure manifesting as lowered energy levels, 
generalised malaise, weight loss, headaches, sleep disturbance, nocturnal and 
subsequent daytime hypercapnia. The concurrent increase in the frequency of 
respiratory infections raises the risk of death from respiratory failure during an 
infection (59, 64). 
Non-progressive cognitive impairment in DMD can reach a maximal range of severe 
intellectual disability (ID) (65, 66). Investigators consistently report the full scale 
intelligence quotient (FSIQ) in DMD patients as slightly below the population mean, 
with FSIQ scores of under 70 points seen in 19–35% of DMD cases, and moderate to 
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severe ID (FISQ<50) noted in 3% of DMD patients (65, 67-69). The gross anatomical 
structure of DMD-affected brains appears normal (22), although other researchers 
found slight cerebral atrophy in 66% of DMD cases, the extent of atrophy correlating 
directly with low intelligence quotient (IQ)(70). There was a relationship between FSIQ 
results and the location of the DMD mutations and correlate with cognitive deficits and 
cumulative loss of dystrophin isoforms expressed in the central nervous (CNS) (65). 
Intellectual disability in BMD patients is reported infrequently, and there is speculation 
that since cognitive disabilities in D/BMD can precede the onset of muscle weakness 
and some cases, X-chromosome-linked mental retardation tends to be seen with 
mutations in the DMD gene (22). 
Dystrophin is also seen in the retina and some patients with DMD show impaired 
scotopic and photopic responses obtained by full-field electroretinogram (ERG) (71). 
Their visual function does not appear to be seriously compromised, although a degree 
of non-progressive, red-green colour-blindness has been documented (72). 
Long bone fractures and fractures of the vertebrae are common in D/BMD, because of 
low bone mineral density, possibly caused by relative immobility, further exacerbated 
by the long-term use of corticosteroids. Progressive loss of mobility along with steroid 
treatment can also lead to excessive weight gain, which in turn leads to early 
immobility. On the other hand, loss of appetite frequently accompanying respiratory 
failure, results in weight loss. Constipation is a frequent complaint in older boys, due 
to the involvement of smooth muscle. In later stages, difficulty in swallowing and 
frequent aspiration creates further nutritional and even respiratory complications. 
D/BMD patients can also potentially presents with “a fatal ‘‘malignant hyperthermia-
like reaction associated with rhabdomyolysis, hyperkalaemia and myoglobinuria” (60), 
when subjected to suxamethonium or a halogenated inhaled anaesthetic (60, 73). This 
rhabdomyolytic risk is a major consideration in their anaesthetic management, and 
easy access to monitoring aids and intensive care facilities is strongly indicated (60). 
D/BMD along with other muscle disorders ranging in presentation from muscle cramps 
and myoglobinuria, to DMD-associated dilated cardiomyopathy or X-linked dilated 
cardiomyopathy (XLDCM), are also referred to as dystrophinopathies, since all are 
caused by production of defective or insufficient levels of dystrophin (74, 75). 
Diagnosis and Genetic Testing for DMD and BMD 
The DMD CARE Consideration Working group in the United States in a recent 
publication in the Lancet, supported by the Centres for Disease Control and Prevention, 
formed a policy on methods used in the diagnosis of and Management of D/BMD (59, 
76). According to the clinical care recommendations, as set out by the group; DMD 
diagnosis should be considered irrespective of a positive or negative family history, 
based upon abnormal muscle function in a boy, elevated serum creatine kinase 
(CK) levels (in DMD massively elevated by 10 – 100 x normal, since birth), a result of 
muscle tissue break down, and including elevated transaminases (76). 
Clinical Suspicion is then confirmed by: 
• Genetic testing:  Mutation detection provides conclusive evidence and 
diagnosis. However, it is worth noting that false negative results are a 
possibility and negative results should be interpreted cautiously as they do not 
exclude D/BMD diagnosis. A good understanding of the test limitations is 
therefore required. Testing the mother’s carrier status is not strictly part of the 
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diagnosis but facilitates genetic counseling of the family (77).  
• Muscle biopsy: Immunohistochemical staining for dystrophin in muscle tissue 
will reveal absent or reduced dystrophin levels, which can be used to confirm a 
diagnosis of D/BMD. In most centres however, because of the invasive nature of 
the procedure, biopsies are taken only if molecular testing is uninformative (59). 
This is the policy for the service at Red Cross War Memorial Children’s Hospital. 
With current techniques, however, efficiency of mutation detection approaches 
100% (78, 79), which allows accurate evaluation of female carriers in a family: 
1. Multiplex PCR, Southern blotting and FISH are utilised and able to detect two 
thirds of mutations in DMD, which are mostly deletions (9, 80). 
2. Duplications are detected by utilising quantitative PCR and Southern blotting 
analysis, which account for 6–10% mutations in males with DMD. 
3. Multiple ligation probe amplification (MLPA) is utilised to analyse genes in 
Carriers and probands, looking at deletions as well as duplications (9). 
4. Splicing mutations, single base changes, small deletions make up around a third 
of DMD mutations. Sequence analysis or mutation scanning is utilised to delineate 
these changes in the gene. 
5. Denaturing gradient gel electrophoresis (DGGE)-based whole-gene mutation 
scanning and (SCAIP) single-condition amplification internal primer sequencing, 
are most recent methods of gene testing, and are utilised to detect the remaining 
third of mutations not yet elucidated by the above tests (81). 
6. Muscle biopsy-based approaches utilising direct cDNA sequencing in 
combination with protein- and RNA-based analyses increase the mutation detection 
frequency to almost 100%(9, 31). 
7. Chorionic villus biopsy or amniocentesis is available as a test for prenatal 
diagnosis by direct testing for abnormalities in the dystrophin gene (9). 
 
 
RECENT ADVANCES ON TREATMENT AND CARE OF DMD 
In the last few years, the natural untreated course of this condition has improved with 
interventions (e.g. corticosteroids, cardiac, respiratory, orthopaedic, rehabilitative etc.), 
quality of life has improved and affected patients may now reach their fourth decade (a 
significant advance on the previous life expectancy of 14 to 19 years. Research into 

















Organ System  Intervention 
Muscular Regular  specialist  health assessments, 
physiotherapy, glucocorticoids, orthoses, 
wheelchair, hoist, electric bed, prevention  of  
malignant hyperthermia 
Respiratory Immunisations, treatment of respiratory tract 
infections, lung function monitoring, pulse 
oximetry study, cough assistance device,  
non-invasive  ventilation, tracheostomy 
Cardiovascular Cardiovascular assessments with ECHO, 
ECG, blood pressure measurements, 
treatment of cardiomyopathy with ACE 
inhibitors and β-blockers 
Gastrointestinal Tract Monitoring diet, teeth, swallowing, bowel 
function and weight gain,  acid  reducers,  
videofluoroscopy, gastrostomy 
Skeletal Bone density tests (DXA), calcium, vitamin 
D, bisphosphonates, surgery for scoliosis 
and joint contractures 
Renal/urogenital Prevention and treatment of dehydration, 
myoglobinuria and enuresis, urinalyses 
Nervous System Speech and language assessment, pain 
and sleep control, learning and 








The role of corticosteroids has become clearer. Glucocorticoids can slow down the 
decrease muscle function and strength in DMD patients and remain the one medication 
currently available for such use; this defers loss of ambulation, leads to a reduction in 
scoliosis and consequently stabilises and improves respiratory function (59, 82). 
Low-dose steroids are very useful when boys are still walking, to improve motor 
function. The time of commencement of steroids remains controversial; currently, 
recommendations are to wait until identifying a plateau in the child’s motor 
development, where motor skills no longer progress and stagnate (59). Once that 
plateau is identified, steroids are commenced; they are not approved for children still 
developing motor skills, especially under 2 years (59, 83). Typically, an affected male 
will progress with motor skills until 4–6 years old. Presently, steroid therapy is the 
preferred treatment for affected patients of the age bracket 5 to 15 years (59, 83, 84). 
Some studies, however, suggest that the ideal window for treatment could be less than 
5 years (85, 86),	where possible our practice is to continue corticosteroid beyond loss of 
ambulation to promote cardiac protection. Restrictions to this practice have been 
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excessive weight gain, patient preference and side effects from the corticosteroids. 
These patients need close monitoring, adjusting dose and timing to avoid unwanted side 
effects, especially weight gain. 
It has been established that prednisone is effective in achieving delay in disease 
progression, prolongation of ability to walk, maintenance of strength and function, 
delay in, or prevention of, development of scoliosis, and preservation of respiratory 
function by limiting fibrosis of the diaphragm (57, 59, 82). The precise mechanism by 
which prednisone exerts a therapeutic effect is unknown, but it is hypothesised that it is 
via a stabilising effect on muscle membranes. Prednisone is immunosuppressive, and 
also has direct effects on muscle cells. It increases the formation of muscle tissue 
(myogenesis) and inhibits natural cell death (apoptosis). Muscle strength increase is 
noticeable within 10 days on a steroid dose of 0.75 mg/kg per day, and this benefit can 
be maintained for 2 years (83). The recommended schedule is daily steroid dosing, 
although other regimens have been used, including 10 days on, 10 days off, alternate 
daily doses or weekly high doses (5–10 mg/kg per week (59, 82). Side effects include 
weight gain, Cushingoid features, hypertension, osteoporosis, hyperglycaemia, easy 
bruising, fat embolism with trauma and usually transient behavioural problems. The 
side effects can preclude its ongoing use, although dose reductions, alternative dosing 
regimens or nocte dosing may overcome these problems. Prednisolone or prednisone 
can be used. Another steroid that is as effective as prednisolone in maintaining muscle 
strength and function is deflazacort (87), a methyloxazoline derivative of prednisone. 
Deflazacort (DFZ) also enhances cardiac and pulmonary function and attenuates the 
development of scoliosis, including when ambulation is lost. DFZ may cause less 
severe adverse side effects (e.g. less weight gain) than prednisone (87, 88). DFZ is not 
freely available, but some neuromuscular specialists use it on individual basis. 
A number of therapeutic approaches are being developed for DMD, but most of these 








Gene therapy trials using new-generation adenovirus carriers known as ‘stealth’ or 
‘gutted’ vectors (containing no original viral genes) are being developed to overcome 
the obstacle of the immune system. Work proceeds on alternative strategies to replace 
the defective dystrophin gene in DMD patients (89). These include ‘exon skipping’, 
where synthetic RNA is used to restore the genetic code to produce partially 
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functioning dystrophin, thereby converting DMD into BMD; and ‘utrophin 
upregulation’, which attempts to increase muscle cell production of ‘utrophin’, a 
protein related to dystrophin, which can substitute or compensate for it if made in 
sufficient amounts. 
Primitive stem cells in bone marrow have been shown to migrate into muscle and 
become new muscle cells (63, 90). However, this is still in experimental stages (63, 
91). Gentamicin has been found to permit myocytes to ignore an abnormal stop codon 
in the dystrophin gene and to proceed and synthesise the protein in the 15% of DMD 
patients who have premature stop codons as their underlying mutation (63, 92). 
PTC124 is a new agent, traded as Ataluren that may permit ribosomal read through of 
nonsense mutations. Morpholino antisense oligonucleotides permit exon skipping.  
The care of DMD is multidisciplinary involving a plethora of specialists: orthopedic, 
cardiac, pulmonology, physiotherapists, dieticians, occupational therapists, 
psychologists, and family and parent/patient support groups.  
• Physiotherapy: passive or active exercise as well as appropriate orthotic 
devices to prevent and treat contractures, scoliosis and for walking and/or 
sitting postural support (seating / wheelchairs).  
• Splinting: as appropriate, depending of the degree of ambulation and ankle 
dorsiflection.  
• Surgery: possible elongation of Achilles tendons and correction of scoliosis.  
• Anaesthesia: careful preoperative assessment of cardiac and respiratory 
function and consideration of the rhabdomyolytic risk. 
• Respiratory management: prophylaxis, prompt diagnosis and treatment of 
lung infections, positive pressure ventilation to treat hypercapnia and 
respiratory failure.  
• Cardiovascular management: regular monitoring of cardiac function 
(echocardiogram and ECG), treatment with ACE (angiotensin converting 
enzyme) inhibitors. Additional agents after onset of symptoms.  
• Bone health Monitoring: diet supplementation using vitamin D and calcium, 
intravenous bisphosphonates for vertebral fractures, early mobilization post 
long bone fracture, to prevent early loss of ambulation.  
• Nutrition: weight monitoring and diet adjustments, use of mild laxatives to 
relieve constipation, intubation or percutaneous endoscopic gastrostomy (PEG).  
• Addressing learning and emotional difficulties: occupational and speech 
therapy, consultation with psychologists and support groups. Planning for 
appropriate school placement and in-school support.  
• Access to adaptive technologies i.e. electric beds / ripple mattresses and wheel 
chairs, computers etc., to aid an independent and functional life (59, 76).  
These current care guidelines, especially corticosteroids use, cardiac interventions, and 
noninvasive ventilation, are all associated better outcomes and quality of life but have 
22	
	
no effect on modifying ongoing disease progression (76, 88, 93) 
 
INTERNATIONAL PERSPECTIVE ON RARE DISEASE REGISTRIES- 
TREAT-NMD 
The different types of variations so far described for the DMD gene range from “large 
deletions, duplications, point mutations, as well as small rearrangements”(2, 94). 
Currently, genetic testing in laboratories is typically done with lack of coordinated 
integrated information-based registries and this places a substantial burden on genetic 
service delivery. Postulated treatment strategies are geared towards alleviating the 
defective gene mutation (92, 95). Finding which type of varaiation is linked to a 
specific DMD phenotype is central to genetic diagnosis and the formation of a 
meaningful research ensuring standard clinical care. Over 7,000 (7,149 as of November 
2013) mutations are currently in the global database called TREAT-NMD DMD (2). 
Locus-specific databases (LSDBs) are important for clinical and phenotypic 
information (2) since they collect, organize, store and analyse all genetic variants of 
disease. The LSDBs known for DMD are the Leiden muscular dystrophy pages in the 
Netherlands (27), and the UMD-DMD in France (8).  
Despite the fact that formation of these databases has lead to the increased awareness 
around disease registries and serves as an essential tool for improving quality patient 
outcomes, yet the number of established national disease registries are still few (96-98). 
No one country has high enough numbers of patients to embark on translational 
research (99). Major setbacks to recruitment into clinical trials are the lack of 
harmonization and the prevailing fragmentation in the neuromuscular community with 
diverse geographic spread of patients. 
Rare diseases, like DMD, are reported to have a low prevalence, however, when 
considered together, they sum up to very large numbers approaching millions in the 
United States, European Union and in Australia (13, 99). There is paucity of rare 
disease prevalence in Africa because of limited resources. Only two national registries 
exist for DMD in Sudan and Algeria. These registries are both linked to the TREAT- 
NMD database in Europe (13). 
There is an evolving urgency for the formation of rare disease registries worldwide, but 
in Africa in particular. Such platforms would be critical in integrating data from 
established rare disease registries and help to form new ones (100) 
There is accumulating evidence that advocacy groups motivate much of the need to 
form rare disease registries (101). Rare Diseases South Africa, a voluntary organization 
providing advocacy, awareness and support for people affected by rare diseases, and 
the Muscular Dystrophy Foundation of South Africa, a registered Non Profit 
Organisation (NPO) whose mission statement is “to support people affected by 
Muscular Dystrophy and Neuromuscular disorders, and endeavour to improve the 
quality of life of their members”, are examples of such advocacy groups in South 
Africa. Internationally, a Network of Excellence, funded by the European Union, was 
launched on the 1st January 2007. This network was named TREAT-NMD and through 
collaboration has enable experts to come together in the process of creating common 
standards of care and bring together the neuromuscular community to speed up clinical 





THE LOCAL PERSPECTIVE AND RATIONALE FOR THIS STUDY 
To follow the efforts of TREAT-NMD through, the dedicated neuromuscular service at 
Red Cross War Memorial Children’s Hospital manages the single largest collection of 
children with Duchenne Muscular Dystrophy in the country. The hospital, as South 
Africa's leading centre for post-graduate specialist paediatric medical and surgical 
training, offers specialised care facilities and high levels of expertise. “The Guidelines 
for Medical approach to Care of Children with DMD – Guidelines from the 
Neuromuscular Clinic”, authored by Professor Jo Wilmshurst, head of Paediatric 
Neurology at RXH (and a clinical supervisor in this study), and approved by PANDA 
SA (Paediatric Neurology and Development Association of Southern Africa) offer a 
clear guide as to the appropriate and achievable standard of care within the South 
African context, based on the recommendations set by international bodies (i.e. US 
Centres for Disease Control and Prevention, DMD Care Considerations Working 
Group). 
The service operates along international lines as a multidisciplinary team with input 
from ancillary services, pulmonology, cardiology, developmental, orthopaedics, 
histopathology, genetics and counsellors.  With the possibility of treatment becoming 
available, patients that would qualify for treatment need to be identified.  The service 
has established a database of these children with confirmed DMD, but there is a need to 
consolidate and expand the information in the database to form a patient registry. 
The South African DMD (SADMD) registry is the first local attempt to consolidate 
clinical and genetic information on South African DMD patients with the potential to 
be considered for contemporary clinical trials and to be well informed regarding the 
most recent and up to date standards of care. This cohort will provide the biggest 
longitudinal data collection of DMD boys in Africa with the possibility to link with 
centres of excellence like TREAT-NMD. 
 
Aim 
This study aim to describe the concept and design of the first DMD disease registry of 
South Africa using Research Electronic Data Capture (REDCap)   
Objectives 
The objectives for forming the registry are: 
• To update and expand the existing database and to populate it with current 
information relating to the clinical phenotypes of the patients inclusive of their 
cardiac, respiratory, cognitive, oromotor / gastroenterological, motor and 
orthopaedic evolution 
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• To assess the effect of introduction of corticosteroid and cardiac interventions
on the course of these children for their cardiac and pulmonary, duration of
ambulation, orthopaedic complications and resultant need for BIPAP support.
• To correlate the clinical profile of this patient group with those who have
confirmed genetic mutations and identify those who may be remedial for the
latest gene therapy and who would benefit from extended screening to confirm
is this is the case.
• To establish if the South African cohort carry a similar range of mutations
compared to those listed internationally.
• To see if direct relationship can be identified between specific mutation and
clinical course.
• To identify if the range of patients carrying potentially remedial gene therapy
mutations is in-line with the incidence reported internationally
8.6 Conclusion 
This study describes the concept and design of the first DMD disease registry of South 
Africa using Research Electronic Data Capture Tool .The accumulated data from this 
cohort will represents the biggest longitudinal data collection of DMD boys in Africa 
and could form a reference for research in the Neuromuscular community. 
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identified. Hence the need for a DMD specific disease registry. 
Objective: This study aim to describe the concept and design of the first DMD disease 
registry of South Africa using Research Electronic Data Capture (REDCap)   
Methods: The registry was developed using REDCap’s web based online designer 
accessed through the Clinical Research Centre (CRC) in the Faculty of Health Sciences 
at the University of Cape Town, and the workflow methodology was adopted to 
manage the registry. Clinical data from DMD patients form the database and consists of 
seven parts: 1) Enrolment details, 2) Background data, 3) Current disease, 4) 
Schooling, career prospects, and life style/psychological details, 5) Basic activity of 
living scale, 6) power Chart, 7) Current motor function/symptoms. Electronic case 
report forms were created from these clinical data by the use of REDCap and for 
specific variables serial entries were possible relating to disease progression. We 
adopted international data standards proposed by TREAT-NMD, a global network of 
registries on DMD to ensure our data is internationalised and comparable to other 
registries. 
Results: Retrospective data entry combined with dynamic prospective recording of 
data was utilized in this project. Building on an existing database, 100 confirmed DMD 
boys are currently eligible for inclusion into the registry. 
The registry database consist of 7 forms collecting information on clinical and genetic 
information, which is subdivided into 100 items making a total of 210 variables. As our 
registry is an on-going study, sequential analysis of accumulated data will done going 
forward to review trends on our DMD patients. 
 
Conclusions: This work described the concept and design of our DMD registry and the 
meticulous steps followed to its establishment with REDCap, the focus is to consolidate 
clinical and genetic information on South African DMD patients that will translate to 
clinical research and form the basis for these patient information to be linked 
internationally. It is the hope that such an effort can be replicated in the 




 The most prevalent, most lethal of the inherited dystrophies is Duchenne Muscular 
Dystrophy (DMD) and globally, the incidence is reported to be 1 in 3500 live male 
births (1-4) 
Variation of the dystrophin gene is what leads to Duchenne, Becker and a third 
intermediate form of muscle disorder, collectively known as the dystrophinopathies (1). 
Muscle fibre degeneration is the primary pathologic process; leading to weakness as the 
principal symptom. 
The different types of variations so far described for the DMD gene range from “large 
deletions, duplications, point mutations, as well as small rearrangements”(2, 5). 
The current care guidelines, especially on corticosteroids use, cardiac interventions, and 
non-invasive ventilation, are all associated with better outcomes and quality of life but 
have no effect on modifying on-going disease progression (6-8). Postulated treatment 
strategies are geared towards alleviating the defective gene mutation (9,10). Finding 
which type of mutation is linked to a specific DMD phenotype is central to genetic 
diagnosis and the formation of a meaningful research ensuring standard clinical care. 
Over 7,000 (7,149 as of November 2013) mutations are currently in the global database 
called TREAT-NMD (2). Despite the fact that formation of these databases has lead to 
the increased awareness around disease registries and serves as an essential tool for 
improving quality patient outcomes, yet the number of established national disease 
registries are still few today (11-13). No one country has sufficient patients to embark 
on translational research (14). Major setbacks to recruitment into clinical trials are the 
lack of harmonization and the prevailing fragmentation in the neuromuscular 
community with diverse geographic spread of patients (15).  
Rare diseases, like DMD, are reported to have a low prevalence, however, when 
considered together, they sum up to very large numbers approaching millions in the 
United States, European Union and in Australia (3,14). There is paucity of rare disease 
prevalence in Africa because of limited resources and only two national registries exists 
for DMD in Sudan and Algeria. These registries are now both linked to TREAT- NMD 
database in Europe (3). 
There is an evolving urgency for the formation of rare disease registries world wide, 
but in Africa in particular. Such platforms would be critical in integrating data from 
established rare disease registries and help form new ones (16) 
There is accumulating evidence that advocacy groups motivate much of the need to 
form rare disease registries (17). Rare Diseases South Africa, a voluntary organization 
providing advocacy, awareness and support for people affected by rare diseases, and 
the Muscular Dystrophy Foundation of South Africa, a registered Non Profit 
organisation (NPO) whose mission statement is “to support people affected by 
Muscular Dystrophy and Neuromuscular disorders and endeavour to improve the 
quality of life of their members”, are examples of such advocacy groups in South 
Africa. Internationally, a Network of Excellence, funded by the European Union, was 
launched on the 1st January 2007. This network was named TREAT-NMD and has 
enabled experts to create common standards of care and bring together the 
neuromuscular community to speed up clinical trials and increase awareness of rare 
diseases like Duchenne Muscular Dystrophy (3). 
Locally in South Africa, the dedicated neuromuscular service at “Red Cross War 
Memorial Children’s Hospital” manages the single largest collection of children with 
Duchenne Muscular Dystrophy in the country. The hospital, as a “leading South 
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African centre for post-graduate specialist paediatric medical and surgical training”, 
offers specialised care facilities and high levels of expertise.  
The service operates along international lines as a multidisciplinary team with input 
from ancillary services, pulmonology, cardiology, developmental, orthopaedics, 
histopathology, genetics and counsellors.  With the possibility of treatment becoming 
available, patients that would qualify for treatment need to be identified.  The service 
has established a database of these children with confirmed DMD, but there is a need to 
consolidate the information in the database to form a patient registry. 
The South African DMD (SADMD) registry is the first local attempt to consolidate 
clinical and genetic information on South African DMD patients with the potential to 
be considered for contemporary clinical trials and be well informed regarding the most 
recent and up to date standards of care. This cohort will provide the biggest 
longitudinal data collection of DMD boys in Africa with the possibility to link with 
centres of excellence like TREAT-NMD. 
 
Aim 
This study aim to describe the concept and design of the first DMD disease registry of 
South Africa using Research Electronic Data Capture (REDCap)   
Objectives 
The objectives for forming the registry are: 
• To update and expand the existing database and to populate it with current 
information relating to the clinical phenotypes of the patients inclusive of their 
cardiac, respiratory, cognitive, oromotor / gastroenterological, motor and 
orthopaedic evolution 
• To assess the effect of introduction of corticosteroid and cardiac interventions 
on the course of these children for their cardiac and pulmonary, duration of 
ambulation, orthopaedic complications and resultant need for BIPAP support. 
• To correlate the clinical profile of this patient group with those who have 
confirmed genetic mutations and identify those who may be remedial for the 
latest gene therapy and who would benefit from extended screening to confirm 
is this is the case.  
• To establish if the South African cohort carry a similar range of mutations 
compared to those listed internationally.  
• To see if direct relationship can be identified between specific mutation and 
clinical course.  
• To identify if the range of patients carrying potentially remedial gene therapy 










“REDCap electronic data capture tool is hosted and managed by the University of Cape 
Town's eResearch Centre and the UCT Clinical Research Centre. REDCap (Research 
Electronic Data Capture) is a secure, web-based application designed to support data 
capture for research studies, providing: 1) an intuitive interface for validated data entry; 
2) audit trails for tracking data manipulation and export procedures; 3) automated 
export procedures for seamless data downloads to common statistical packages; and 4) 
procedures for importing data from external sources.” 
Vanderbilt University developed the REDCap application but it is available free of 
charge to institutional partners that satisfied the basic criteria for a web server that 
supports, secure sockets layers (SSL), PHP, MySQL database connections (18,19). 
UCT satisfied all these criteria and has become a REDCap consortium member.   
DMD Patients  
All patients with confirmed DMD diagnosis (or pending diagnosis) according to DNA 
confirmation or compatible confirmation on muscle biopsy or with a confirmed 
affected relative where there is compatible X-linked inheritance are eligible for 
inclusion. Currently, only children managed through the Red Cross War Memorial 
Children’s Hospital neuromuscular service will be included, as these patients receive 
standardised and consistent care protocols which are not routine in other SA centres 
with less capacity, at this stage. Collaboration with the genetics service research team 
was undertaken exploring the known genetic mutations of these patients in relation to 
their clinical profile and their potential to undergo further screening for gene therapy. 
Exclusion criteria for this database are patients referred with a presumed diagnosis of 
DMD/BMD who subsequently were found to have other pathologies. Similarly patients 
suspected to have DMD/BMD but who lacked the definitive diagnostic closure via 
DNA analysis or muscle biopsy or family history, were also excluded. In isolated cases 
patients with known DMD were excluded where there was insufficient information 
documented or they were lost to follow-up.  
The protocol for this study, the patient information and authorization (Appendix 2) and 
relevant supporting information were all submitted, reviewed and approved by the 
“Hospital Research Committee and the University of Cape Town Human Research 
Ethics Committee”. 
For every patient and carer, appropriate patient/caregiver assent/consent will be 
obtained according to South African regulations. As the study is non-invasive and 
collating existing data, telephonic consent could be taken initially and formally signed 
at the caregiver’s convenience when they attend the clinic. This is to ensure that all data 
is current by the time the current actual therapeutic interventions are available that the 
viable patients are already identified. There will be a clear explanation to the 
patient/caregiver in his or her own language, supplemented with a patient/ care giver 
information sheet (Appendix 2) which will be given to the patient/ caregiver to read and 
consider prior to enrolment.  
Patients and caregivers will be invited to give permission for the clinical data to be 
registered on the RCWMCH DMD database. If they choose for their personal and 
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medical data to be uploaded in the database, it will be stored in accordance with the 
data protection act and pseudonymised. Encrypted data will then be saved in the 
database. 
Patients and their caregivers participate voluntarily in this study with the option not to 
participate or withdraw consent for their data to be stored on the registry/database at 
any time without prejudice. Patients and caregivers will be reminded that they may 











The enrolment and background data forms are developed to capture mandatory set of 
data including age at presentation, first symptoms at presentation, demographics, 
family history, referral route, and initial creatinine kinase values. This mandatory 
section is crucial for a meaningful data collection going forward so that each patient 
will have a minimum amount of information recorded. The rest of the items focus on 
DMD defined clinical manifestations and such data are collected in other sections of 
the registry listed above, repeated annually, and as appropriate. Self reported Activities 
of Daily Living (ADL) is to capture patient’s reported QOL on an annual basis to 













The registry operates on a longitudinal module and utilises the repeating events feature 
of REDCap, which allows one to repeat an entire event of instruments together in 
unison. This is useful for several instruments whose data correlates together. The 
repeating events feature allows one to create only one single event that can be repeated 
in an unlimited fashion. 
Hospital clinical records and clinic visits records are our main sources of data, 
prospectively and retrospectively on an annual basis starting from the first documented 
visit to the Neuromuscular Service of RCWMCH, this will continue as a dynamic data 
collection. 
Statisticians and Information technology (IT) specialists reviewed the database design 
and planning process and provided detailed advice on the methodology and data items. 
Authenticated users of smaller scale neuromuscular centres will be provided access 
Following a key recommendation of TREAT-NMD on creating registries for rare 
diseases, the SADMD system is developed with the aim to become an open-source 
software solution. The REDCap framework was chosen as it allows rapid prototyping 
and its flexibility makes it easy to customise the application such as adding additional 
fields or options. It provides a very powerful and easy to use ORM (Object-relational 
mapping) to build Complex SQL database queries. Its template engine allows the 
development of user-friendly interfaces, with HTML/CSS and Javascript. It is also very 
well integrated with the Apache Web server for deployment in production 
environments. 
As with most authentication-based systems, the SA National Duchenne Muscular 
Dystrophy Registry in the future can be most broadly broken into two sections: the 
component available to unauthenticated users and the part available to authenticated 
users. 
Only one page of the DMD Registry will be available to unauthenticated users: a 
landing page explaining the aims of the registry and linking to the government and non-
profit stakeholders within the project.  
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associated with a particular working group, with patient data access being restricted 




Creating the Registry database 
The REDCap was used to create and run the DMD registry,  “it is a secure, web-based 
application designed to support data capture for research studies, providing: 1) an 
intuitive interface for validated data entry; 2) audit trails for tracking data manipulation 
and export procedures; 3) automated export procedures for seamless data downloads to 
common statistical packages; and 4) procedures for importing data from external 
sources (20); 5) as well as a built-in project calendar, a scheduling module, ad hoc 
reporting tools, and advanced features, such as branching logic, file uploading, 
calculated fields and possibility of  creating surveys for quick feedbacks”(19-21). 
The REDCap server provides training videos and teaching resources on REDCap to 
guide users, a formal training or prior experience is not required to use the application. 
Nonetheless, the main administrator for REDCap at UCT was consulted to assist with 
project programming, and guide on data quality and security and to agree with the 
standard operating procedures. The implementation stage included:  I) UCT network 
access to REDCap by logging with staff/ student credentials, II) Clicking on to the 
“Create New Project” icon to create and designed the project III) Defining variables 
and their properties to enable you to create data collection instruments, IV) Dataset 
preview and testing in anticipation for statistical output and analyses, v) Providing 
rights and permission to users, VI) Switching Project to production mode for real data 
collection.  
Data entry and Quality 
Data entry errors are a possibility and test runs are important to try to curtail errors as 
much as possible. REDCap data quality module allows for execution of data quality 
rules upon project data to check for discrepancies in data, this feature was utilised in 
this project and predefined rules filtered errors and discrepancies. These predefined 
rules were important since our project constitutes many fields and records. Data 
validation was possible as a REDCap feature by limiting   data sets and set ranges for 
numerical data fields, the data quality module reports any values out of range, incorrect 
data type and outliers.  
The main investigator pioneered the data extraction and input, with review, adjustments 
and additions by the supervisor. 
The supervisor ensured that standard operating procedures were adhered to strictly, 
especially data entry and collection. Statisticians will be were consulted on a   6 
monthly basis for quick checks. The allowance for entry mistakes is 5 per 100, 





This project is primarily managed by the neuromuscular service of the RCWMCH, 
headed by the Project administrator, Professor Jo Wilmshurst who oversees the entire 
functioning of the project including personnel associated with data entries. The team 
work closely with statisticians and IT specialists of the University of Cape Town's 
eResearch Centre and the UCT Clinical Research Centre who advised on the database 
structure and design. The main investigator developed the electronic data collection 
forms and the IT specialists and statisticians review them. The neuromuscular service 
team recruited and attained consent/assent from subjects for the study if they met  















Retrospective data entry combined with dynamic prospective recording of data was 
utilized in this project. Building and expanding on an existing database, 100 confirmed 
DMD boys are currently eligible for inclusion into the registry. 
Structure of the registry 
The registry database consist of 7 forms collecting information on enrolment, 
background details, current disease, schooling/ career prospect, activities of daily 
living, power chart, current motor function/symptoms, which is subdivided into 100 
items making a total of 210 variables as shown in Table 1 
Table	2	DMD	registry	structure,	NIV,	noninvasive	ventilation,	BMI,	body	mass	index,	CPK,	creatinine	
phosphokinase	
Enrolment details Study ID, Consent/Assent done, Date subject signed 
consent, Currently included in a clinical trial/study, 
Trial/study name, Name of person doing the entry, name, 
date of birth, age, gender, address, next of kin, ethnicity, 
race, primary condition, diagnosis code, presumed clinical 
subtype, date diagnosed, age at diagnosis, muscle biopsy 
details, genetic details, gene therapy eligibility 
Background information Age at first symptoms, type of symptoms presented with, 
hospital admissions and reason for admission, best motor 
function, wheel chair use, age of starting wheel chair use, 
type of wheel chair, source of wheel chair, type of wheel 
chair, age of complete loss of ambulation, family history 
of DMD, CPK test details, referral details of patient 
Current Disease on 
annual basis 
Weight, height, BMI, respiratory involvement and 
respiratory co-morbidity, NIV, form of NIV, indication 
for NIV, type of NIV, form taken, tracheostomy details, 
special investigations, lung function details, chest 
infection episodes, result of polysomnography, need for 
pulmonology referral and reasons for doing so, chest 
physiotherapy details, steroid use, date steroid started and 
reason for starting, current steroid dose and regimen, side 
effects so far. Scoliosis and cardiac involvement, Bone 




School curriculum, life style, and psychosocial issues like 
education on DMD, emotional issues, social support, and 
support grant, type of support grant. 
Basic activities of 
dialing living 
Bathing, dressing, toileting, transferring, continence, 
feeding 






Able to walk, able to run, able to climb stairs, arm 
involvement, participates in sports, myalgia, time myalgia 
is experienced 
 
Clinical data standards 
This registry has been set-up on the background of clinical and translational research 
readiness in mind. In this regard, we have collected dataset that is concise and guided 
by pertinent aspects of required inclusion criteria for clinical research known as 
mandatory dataset. The variables and items described above are all based on 
standardised elements proposed by TREAT-NMD data standards (3), the defined data 
set allows a coordinated approach to clinical trial readiness and our records to be 










Displayed below is a screen short (Figure 3) showing part of current responses and 
records with their status for every event and data collection instrument. Clicking on a 
button opens a new tab/window in the browser to view that record on that particular 
data collection instrument. We provide form-level user privileges to restricted certain 
data collection instruments, so that users can only be able to view those instruments, 
and if they if they are provided with user rights Data Access Group (DAG), making 
them able to view records assigned to that user group. 
This also shows the enrolment visit (Visit 0), and annual visits. On enrolment, all 
instruments are administered or completed for baseline minimum data on all patient, on 
annual visit, the enrolment form and background data are not repeated, but the rest of 
the instruments are repeated to be able to look at trends. This task is possible by 
utilizing the repeat instrument functionality of REDCap. 
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Figure	3	Screen	shot	of	part	of	the	DMD	registry,	status	dashboard 
Security of Data 
Users are granted access to this project and user privileges of those users are managed 
by the project administrator, this provides complete patient confidentiality since all 
information are encrypted in the Redcap server.  Roles are created to which users are 
assigned (optional). User roles are useful when there are several users with the same 
privileges. Roles and rights can be given for access many tasks ranging from managing 
participants, file repository, logging, data export, data import, data entry rights, project 
design, calendar, to data quality. Logging is required for every encounter with the data, 
an audit tract. The registry administrator has, in addition, the privilege to lock the data 
after all finalisation checks. UCT unique user names and passwords are required for 








Our database was designed to collect mandatory baseline data on all subjects, followed 
by annual updates of data collection by combining retrospective data collection with 
ongoing prospective entry of data records. 
The project brought forward a host of advantages to using the REDCap application for 
registry design and pointed out few challenges encountered in the design of the 
electronic case report forms (eCRF). 
The ease of form construction was noted to be a major advantage. Forms were created 
by a point and click interface on the web; data dictionaries externally created in excel 
can be uploaded. Moreover, the University of Cape Town's eResearch Centre and the 
UCT Clinical Research Centre technical team allowed quick answer to questions 
regarding technical difficulties in the design particularly on the use piping and 
branching logic etc.  
Equally important on using the REDCap application was the clear and easy way of 
creating customised reports and exporting the data. Multiple data formats can be 
exported for use in various statistical soft wares. 
Rapid quality assessment, associated with the software, made it possible to identify 
data errors, which were corrected by the neuromuscular team on a continuing basis. 
Data elements and entry forms are specific; this was an advantage in avoiding errors on 
entering records. 
However, challenges and limitations were identified in the creation of this registry 
using the REDCap application. This was illustrated at the time piloting of data began, 
entry form problems were noted, this warranted the REDCap main administrator to 
archive the old entry forms, temporarily take down the database, fixe the errors, and re-
start the database. Therefore, meticulously reviewing of the data instruments prior to 
and testing and retesting them rigorously and imaginatively before going into 
production are encouraged. 
Nonetheless, these limitations and challenges are not major when compared to the rest 
of the advantages stipulated above. This registry demonstrates that the REDCap is 
indeed an effective tool in collecting research and clinical data. 
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9.6 Discussion 
This Duchenne Muscular Dystrophy registry is built on the foundation of need to 
consolidate clinical and genetic information on South African DMD patients. Clinical 
and translational research is needed and should be based on the most recent and up to 
date standards of care. In this manuscript, we describe the concept and design of our 
DMD registry. We adopted a diversity of steps including: meticulous database 
planning, the use of REDCap to construct the electronic case reports forms, as well as 
adopting clinical data standards. 
This study method is also an attempt to follow through international efforts in data 
consolidation through a reproducible research protocol, making it possible for 
replication to other medical registries. To conform to this, we adopted international data 
standards proposed by TREAT-NMD, a global network of registries on DMD, funded 
by the European Union. This allows for internationalisation of our registry, accordingly 
we followed the defined standard items recommended by TREAT-NMD (3, 16), as 
well as data elements from other international designs such as rare disease HUB (100, 
105). Electronic information in health systems is now recognised and accepted in the 
international community making it crucial to adopt established data standards. 
Consequently, this means a more versatile registry and the possibility of our registry 
being able to collaborate with other institutions like TREAT-NMD. 
Successful workflow models aligned to the daily and clinical practice with minimal 
interruption has produced successful registries (12, 16, 19, 23), in our work, we have 
made an effort to align the clinical services of the neuromuscular unit to consenting and 
asking patients and care givers to allow for their information to be uploaded. 
Our data collection primarily focuses on, background information, diagnosis, 
interventions, genetic data, which are all essential to identifying subjects eligible for 
clinical and translational research. 
As our registry is an on-going study, sequential analysis of accumulated data will done 
going forward to review trends on our DMD patients, as a result this will aim to 
provide evidence-based decisions for DMD patients in our setting. The registry data 
will be used to assess the effect of introduction of corticosteroids and cardiac 
interventions on the course of these children for their cardiac and pulmonary, duration 
of ambulation, orthopaedic complications and resultant need for BIPAP support. Also 
to correlate with the clinical profile of this patient group with those who have 
confirmed genetic mutations and identify those who may be remedial for the latest gene 
therapy and who would benefit from extended screening to confirm if this is the case. 
To establish if the South African cohort carry a similar range of mutations compared to 
those listed internationally. Lastly to see if direct relationships can be identified 
between specific mutations and clinical course, as well as to identify if the range of 
patients carrying potentially remedial gene therapy mutations is in-line with the 
incidence reported internationally. 
 9.7 Conclusion 
This work describes the concept and design of a DMD registry and the detailed steps 
followed for its establishment with REDCap. The focus is to consolidate clinical and 
genetic information on South African DMD patients that will translate to clinical 
research and to form the basis for these patients’ information to be linked 
internationally. It is the hope that such an effort can be replicated in the 
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